Sociodemographic, Constitutional Risk Factors Associated with Likelihood of Skin Examinations
the Cancer Therapy Advisor take:
The likelihood of recent screening for skin cancer among individuals was strongly associated with sociodemographic and constitutional risk factors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
In this study, 50,044 participants of the California Twin Program self-reported data regarding prevalence and determinants of recent clinical screening for skin cancer.
Results showed the reported prevalence of skin examination (32% of participants across all ages reported having a skin examination) was greater than the national estimates.
Major factors significantly associated with recent screening included white race, highest level of education, marital status, number of large moles, and both individual and family history of skin cancer.
Whereas, lower socioeconomic status, racial minority status, and frequent UV-related risk behaviors throughout adulthood correlated to a lower likelihood of recent screening among participants.
The likelihood of recent screening for skin cancer among individuals strongly associated with sociodemographic and constitutional risk factors.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC